Antiproliferative activity of N 6-isopentenyladenosine on HCT-15 colon carcinoma cell line by M. Rajabi et al.
Antiproliferative Activity of N6-Isopentenyladenosine
on HCT-15 Colon Carcinoma Cell Line
Mehdi Rajabi,1 Jamshid Mehrzad,1 Elena Gorincioi,2,3 and Enzo Santaniello2
N6-Isopentenyladenosine (iPA), a member of the cytokinin family of plant hormones, exerts remarkable inhi-
bition on tumor cell proliferation and apoptosis in several tumor cell lines. In this study, we report that iPA is
able to inhibit the proliferation and promotes apoptosis in HCT-15 human colon cancer cells in a dose-dependent
manner with a concentration of 2.5 mM, which causes 50% inhibition of cell viability. The cell cycle analysis by
flow cytometry showed that iPA-induced growth arrest could be associated to apoptosis. Moreover, suppression
of clonogenic activity occurs after exposure to iPA at a concentration of 2.5 mM for HCT-15.
Introduction
N
6-Isopentenyladenosine (iPA; Fig. 1) is present as a
free modified nucleoside found in transfer RNA
(tRNA) in yeast (Laten and Zahareas-Doktor, 1985) and as
well as in mammalian cells (Burns et al., 1976; Vold et al.,
1982; Kersten, 1984).
Many biological effects, both in plants and animal systems,
also including antitumor effects on human and murine cells
can be attributed to iPA. Recently, we demonstrated that iPA
inhibits the growth of MCF-7 breast cancer cells in a dose-
dependent manner with interference on cell cycle, which
showed that iPA-induced growth arrest could be associated to
apoptosis (Rajabi et al., 2010). iPA has been reported to induce
differentiation of human leukemia cells (Ishii et al., 2002), to
inhibit proliferation of a Kras- transformed rat thyroid cell
line (Laezza et al., 2006) and to exert anti-leukemic activity
against a mouse leukemia cell line (Chang and Hacker, 1982).
Laezza et al. (1997) demonstrated that iPA influenced cAMP-
dependent organization of themicrofilaments in a thyroid cell
line (FRTL-5 cells) by decreasing cAMP levels, subsequently
by inhibiting DNA synthesis. Spinola et al. (2007) have shown
that iPA exerts potent in vitro antitumor activity on human
epithelial cancer cells. This inhibition of cell growth is paral-
leled by the upregulation of genes involved in arresting cell
cycle, as demonstrated by gene expression profile of iPA-
treated cancer cells (Colombo et al., 2009). It has been also
described that the iPA apoptotic effects on a human carci-
noma colon cancer cell line DLDwas mediated by a sustained
phosphorylation and activation of c-Jun N-terminal kinase
( JNK) that caused, in turn, an increase of c-Jun phosphoryla-
tion (Laezza et al., 2009). The above controversial observa-
tions on the apoptotic mechanism of iPA led us to continue
our studies on iPA activity. We present in this report our
results on the dose-dependent cell cycle arrest and apopto-
genic effect of iPA on HCT-15 colon cancer cell line.
Materials and Methods
Reagent
Trypsin, trypan blue, antibiotic and antimycotic agent, fetal
bovine serum (FBS), sulforhodamine B (SRB), and dimethyl
sulfoxide (DMSO) were purchased from Sigma Chemical Co.
Chemicals and solvents for iPA synthesis were from Sigma-
Aldrich Italia. Sterile flasks of 25 and 75 cm2, sterile and lidded
polypropylene culture tubes, sterile microplates with 24 and
96 wells, and sterile cryo-tubes were obtained from SPL Life
Science Co.
Chemical synthesis of iPA
iPA was prepared following the methods described by Ro-
bins (Robins et al., 1967). Briefly, reaction of adenosine with
isopentenyl bromide affords iPA in 40%–50% overall yield. An
alternative procedure required more expensive compounds
such as 6-chloropurine riboside and isopentenylamine, but
pure iPA can be prepared in 82%–85% yield.
Cell line and culture
Human colon cancer cell line HCT-15 was supplied from
the American Type Cell Culture Collection and maintained
in the standard medium and grown as a monolayer in
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Dulbecco’s modified Eagle’s medium (DMEM) containing
10% FBS, 2mM glutamine, 100U/mL penicillin, and 100 g/
mL streptomycin. Cultures were maintained at 37C with 5%
CO2 in a humidified atmosphere and were passaged weekly
using 0.25% trypsin.
In vitro evaluation of cytotoxic activity
Cell viability or growth activity of iPA in vitrowas evaluated
by the SRB assay (Rajabi et al., 2010). iPA stock solutions
(10mM in DMSO) were prepared and stored at 4C and were
diluted with DMEM to 0.1–1mM range at room temperature
before experiment. The final percentage of DMSO in the reac-
tion mixture was less than 1% (v/v). Cancer cells (2· 103 cells/
well) were plated in 5 multiple in the 96-well plates and incu-
bated in medium for 24 hours. Serial dilutions of individual
compounds were added. The microtiter plates were incubated
at 37C, 5% CO2, 95% air, and 100% relative humidity for 72
hours before addition of iPA. The assay was terminated by the
addition of 50mL of cold trichloroacetic acid (final concentra-
tion, 10% trichloroacetic acid postal) and incubated for
60 minutes at 4C. The plates were washed 5 times with tap
water and air-dried. SRB solution (50mL) at 0.4% (w/v) in 1%
acetic acid was added to each of the wells, and plates were
incubated for 30 minutes at room temperature. The residual
dye was removed by washing 5 times with 1% acetic acid. The
plates were air-dried or under hood. Bound stain was subse-
quently eluted with 10mM trizma base, and the absorbance
was read on an ELISA plate reader at a wavelength of 540nm
and used as a relative measure of viable cell number. The
percentage of growth inhibition was calculated by using
the equation: percentage growth inhibition (1-At/Ac)· 100,
where At and Ac represent the absorbance in treated and con-
trol cultures, respectively. IC50 was determined by interpola-
tion from dose–response curves.
Evaluation of cell morphology
HCT-15 cells plated at about 20,000 cells/well on chamber-
slides (8 wells) were treated with 0, 1, 5, and 10mM of iPA for
72 hours. After rinsing in phosphate-buffered saline (PBS),
cells were fixed in methanol 100% and photographed using a
Nikon camera attached to the microscope.
Cell cycle analysis
Apoptosis and cell cycle profile were assessed by flow
cytometry. HCT-15 cells were plated at a density of 5 · 105
cells/well on 6-well plates. Treated cells with iPA at concen-
tration of 5 mM for 72 hours were harvested, rinsed in PBS,
FIG. 1. Structure of N6-isopentenyladenosine (iPA).
FIG. 2. (A) Effects of iPA
on the proliferation of HCT-
15 cells. Dose of compound
required to inhibit cell
growth by 50% compared to
untreated cell controls. All
experiments were carried
out in triplicate wells and
each experiment was re-
peated twice. (B) Inhibition
growth of iPA on HCT-
15 cells. The percentage
of growth inhibition was
calculated by using the
equation: (1 -At/Ac) · 100,
where At and Ac represent
the absorbance in treated
and control cultures, re-
spectively. IC50 was deter-
mined by interpolation from
dose–response curves. (C)
Morphological analysis of
the effects of iPA on HCT-
15 cells after 72 hours of in-
cubation.
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suspended in 600 mL of PBS containing 1% FBS, fixed by
1.4mL 80% ethanol, and stored at -20C in fixation buffer.
Then, the pellets were suspended in 1mL of fluorochromic
solution [0.08mg/mL propidium iodide (PI) in 1 ·PBS] at
room temperature in the dark for 60 minutes. The DNA
content was analyzed by FACScan flow cytometer (Beckman
Counter, cytomics FC 500) and CellQuest software (Becton
Dickinson). The population of apoptotic nuclei (subdiploid
DNA peak in the DNA fluorescence histogram) was ex-
pressed as the percentage in the entire population.
Clonogenic assays
HCT-15 cells were plated at a density of 700 cells/well
in 12-well plates and treated with 0, 1, 2.5, 5, 10, and 50 mM for
14 days. Plates were rinsed in PBS and colonies were metha-
nol-fixed and stained with 10% Giemsa and were counted
under a light microscope.
Results
Cytotoxic evaluation in vitro and cell shape study
In the presence of different doses of iPA, the cells were
inhibited ranging from 10% to 90% with a loss of viable cells
(Fig. 2A). iPA inhibited the proliferation of HCT-15 cells in a
concentration- and time-dependent manner. The viability of
the HCT-15 cells was almost unaffected by less than 0.2 mM
of iPA treatment for 72 hours, but changed to 80%, in response
to 0.5 mMof iPA, respectively. However, viability decreased to
50% in response to 2.5 mM iPA and continued to decrease as
the concentration of iPA was increased, and was 10% with
10 mM and 5% with 20mM iPA exposure. Thus, it was evident
that iPA was almost noncytotoxic in vitro up to a dose of
0.2 mM. By employing the SRB assay, 50% inhibition of cell
viability (IC50) by iPA was established at a 2.5 mM concen-
tration at 72 hours of treatment (Fig. 2B). Cell shape and
morphology of treated and untreated (control) cells were
viewed using an inverted phase-contrast microscope. Figure
2C shows the incubation of the cells with different iPA con-
centrations and 72 hours of treatment. Control group showed
regular polygonal shape and cell antennaswere short. The cell
morphology of treated cells was affected by iPA treatment
and loss of adhesion, rounding, cell shrinkage, and detach-
ment from the substratum was evident (Fig. 2C).
Apoptosis and cell cycle analysis
To study the mechanism of the antiproliferative activity by
iPA inmore details, we analyzed the effects of iPA treatment on
cell cycle distributions of HCT-15 cells. Cells were treated with
various concentration of iPA for 72 hours and subjected to
FACS analysis after PI staining of the chromosomal DNA. In
histograms of FACS analysis, untreated proliferative HCT-
15 cells showed cell cycle distributions of 69% in G1/G0, 9% in
S, 14% in G2/M, and 8% in sub G1/G0 phase. At concentration
of 5mMiPA leads to an increase in the percentage of cells inG2/
M and in sub G1/G0 phases. At the same iPA concentration,
populations reached 24% for G2/M and 19% for sub G1/G0
phase (Fig. 3A, B) and did not change the duration of the cell
cycle in S andG0/G1 phases. These data indicate that iPA could
arrest HCT-15 cell growth in G2/M phase inducing apoptisis.
FIG. 3. Flow cytometric analysis of HCT-15 cells. Values
are expressed as percentage of the cell population in the G0-
G1, S, and G2/M phase of cell cycle (A) and cell cycle analysis
of HCT-15 cells treated with 0 and 5mM iPA (B).
FIG. 4. Dose–response curve of iPA-mediated inhibition of
HCT-15 cell colony formation. Seven hundred cells were
plated in 12-well plates, treated with various dose levels of
iPA, and stained after 14 days of treatment, and colonies
were counted by microscopy.
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Clonogenic assays
Analysis of clonogenic activity in HCT-15 cells treated with
iPA at concentrations ranging from 1 to 50 mM of iPA for 14
days revealed a complete inhibition of colony formation at
50 mM for HCT-15 colon cells, whereas concentrations lower
than 1mM were almost ineffective (Fig. 4). Linear regression
analysis indicated a highly significant association between
colony number and concentration of iPA treatments.
Discussion and Conclusion
Recently, N6-isopentenyladenosine (iPA) has been shown to
act by inhibiting DNA synthesis, causing a cell cycle arrest
that correlates with a decrease in the levels of cyclin E, cyclin A,
and cyclin D1 and with a concomitant increase in the levels
of cyclin-dependent kinase inhibitor and p27kip1 Moreover,
iPA induces apoptosis through the downregulation of anti-
apoptotic products and caspase-3 activation. In the present
study, our results show that the cytotoxic effect of iPA on
human colon cancer HCT-15 cells is dose dependent with an
IC50 value of 2.5mM at 72 hours of treatment. This causes ap-
optotic morphological changes in cells such as loss of adhesion,
rounding, cell shrinkage, anddetachment from the substratum.
The cell cycle analysis by flow cytometry showed that there
was a increase in the amount of sub-G1/G0 and G2-M phase by
iPA treatment, which indicates that iPA could arrest HCT-
15 cell growth in G2/M phase inducing apoptisis. This increase
of hypoploid DNA is an indication of the inhibition of cell
growth through a mechanism of apoptosis that has been sug-
gested also for other cell lines (Laezza et al., 2009; Rajabi et al.,
2010). Moreover, suppression of clonogenic activity occurs af-
ter exposure to iPA at a concentration of 2.5mM for HCT-15.
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